Navigation Links
Radioimmunotherapy deemed safe and effective for lymphoma patients
Date:7/10/2013

Reston, Va. (July 10, 2013) A new treatment option for patients with relapsing follicular, mantle cell and other indolent B-cell lymphomas has been determined safe and feasible by researchers exploring the potential of a low energy beta-emitter radiopharmaceutical. According to data published in the July issue of The Journal of Nuclear Medicine, the use of 177Lu-DOTA-rituximab as a radioimmunotherapy results in a high rate of tumor response while using less radiation than current therapies.

"Twelve years ago, when we started the study, it seemed that radioimmunotherapy could be a highly interesting tool that was both easy for clinicians to use and well-tolerated in patients. It also was clear that the use of iodine radionuclides was inconvenient for handling and not practical for patients because of the need for prolonged in hospital days due to radiation protection measures," said Andreas Lohri, MD, lead author of the study "Radioimmunotherapy with 177Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas." "Although 90Y ibritumomab tiuxetanZevalinwas introduced shortly after we started the study, we felt it was important to do clinical experiments with other radionuclides."

The prospective study included 31 patients with histologically confirmed relapsed or refractory CD20-positive B-cell lymphoma. All patients received an initial dose of 740 MBq/m2 body surface area of 177Lu-DOTA rituximab.. Doses were increased in steps of 185 MBq/m2 over a maximum of seven doses. Hematologic and nonhematologic toxicity was measured weekly up to week 10 or until recovery from the lowest level of blood cell count. Imaging with whole body computed tomography (CT) and 18F-FDG positron emission tomography (PET) or 18F-FDG PET/CT was conducted at baseline and at 8-12 weeks.

The maximum tolerated dose using 177Lu-DOTA rituximab was 1,665 MBq/m2. Toxicity was mainly hematologic, with thrombocytopenia and leukopenia noted as the dose-limiting toxicities, and nonhematologic toxicity was minor. Clinical responses occurred at all dose levels for patients with follicular (82 percent overall response rate) and mantle cell (21 percent response rate) lymphomas. With a median follow-up of almost seven years, the estimated median time of survival after radioimmunotherapy was four years.

"With 177Lu-DOTA Rituximab we can essentially do CD20 imaging," said Lohri. "At the moment, this may be academically interesting and could potentially be used in daily practice if compared to all forms of current PET imaging."


'/>"/>

Contact: Susan Martonik
smartonik@snmmi.org
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Related medicine news :

1. Radioimmunotherapy could extend lives of advanced lymphoma patients
2. Talk Therapy Can Ease Depression, But No Single Type Deemed Best
3. Airports in N.Y., L.A., Hawaii Deemed Worst for Pandemic Spread
4. Study shows SBRT for stage I NSCLC safe and effective
5. New research finds flu shot effective regardless of circulating flu strain
6. Virus combination effective against deadly brain tumor, Moffitt Cancer Center study shows
7. Long-term study reports deep brain stimulation effective for most common hereditary dystonia
8. Effective Environmental Services Launch New Websites to Serve Customers
9. Provant CEO, Heather Provino, Shares Key Insights on Employee Engagement & Effective Incentive Program Design at SHRM
10. Alta White Teeth Whitening System Now Available in New Package for Effective Results at Home
11. Animal thyroid extract as effective as T4 in treating hypothyroidism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 09, 2016 , ... A new leadership team for Mid-South ... President Joe Wiley made the announcement Monday night, Feb. 8, prior to the evening ... of FHU and the creator of GO! Camp, has been named director. Gayle McDonald, ...
(Date:2/10/2016)... (PRWEB) , ... February 09, 2016 , ... ... at Clevens Face and Body Specialists are delighted to welcome a new addition ... joins Clevens Face and Body Specialists as a nurse practitioner performing cosmetic ...
(Date:2/10/2016)... ... February 09, 2016 , ... Traumatic ... cause of injury may be one of many possible sources: sports, car accidents, ... Education Course , Mastering Rehab Solutions for the Complexities of Concussions ...
(Date:2/9/2016)... Florida (PRWEB) , ... February 09, 2016 , ... Steven ... the Taste of South Florida Event, an upscale fundraiser held in South Florida. The ... sponsors and guests alike. This year the event will be held in a new, ...
(Date:2/9/2016)... ... February 09, 2016 , ... Interstate Restoration LLC, a full ... today the acquisition of Hawaii DKI. Hawaii DKI is one of the more ... companies who excel at service and response helps support our goal of becoming ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Blood Monitoring & Cardiac Monitoring Devices Market Assessment & Forecast: 2015-2019" ... market for blood monitoring & cardiac monitoring devices was valued at ... 24,830.1 million by 2019 at a CAGR of 6.8% from 2015 ... Europe , Asia-Pacific , Latin ... Africa . The three major factors determining growth of the ...
(Date:2/9/2016)... , Feb. 9, 2016  Increasingly, health care ... their vital signs with wireless technology. With the Vios ... automate patient oversight and remotely detect problems before they ... signs across in-hospital environments. the United ... United States . --> The ...
(Date:2/9/2016)... , Feb. 9, 2016  Johnson & Johnson (NYSE: ... Markets Global Healthcare Conference on Tuesday, Feb. 23, at ... Dominic Caruso , Vice President, Finance & Chief Financial ... will represent the Company in a session scheduled at ... --> www.investor.jnj.com . --> This ...
Breaking Medicine Technology: